MUCOSAVE™FG is a blend of two herbal extract containing polysaccharides of prickle pear cladodes (Opuntia cus indica (L.)) and biophenols of olive leaves (Olea europaea (L.)).
MUCOSAVET™FG is a unique combination specifically created for mucosal treatment and to counteract the main symptoms caused by gastrointestinal disorders.
Gastrointestinal (GI) discomfort, which often includes gastroesophageal redux disease (GERD) is a common disorder in healthy adults affecting 20% of the worldwide population. Common symptoms include heartburn, regurgitation and nausea. There is a need for effective natural treatments without harmful side effects to address this problem.
MUCOSAVE™FG is the innovative and natural ingredients to improve the GUT HEALTH.
Opuntia cus-indica is the most widespread cactus into the Mediterranean lands. To survive in a dry climate, the plant uses its “leaves” (cladodes) to save water. Under the prickly surface, the cladodes contain a juicy soft gel filled very rich in polysaccharide.
The Opuntia ficus-indica cladodes, polysaccharide-containing, are used in folk medicine for their wound- healing activities and are widely employed for the treatment of mucous membrane irritation.
Olea europaea, is a species of tree in the family Oleaceae, found in the Mediterranean Basin. The first known record of olive leaf comes from Ancient Egypt. It has since been used extensively in traditional medicine and is still popular across many cultures today.
The phenolic compounds present in olive leaves, are associated to antioxidant, and lenitive activity. The unique combination of biophenols in the olive leaf have many potential health benefits.
MUCOSAVE™FG has a strong mucoadhesive ability thanks to the Opuntia polysaccharides and a lenitive effect from olive biophenols to protect the sensitive mucosae. Thanks to this combination, MUCOSAVE™FG improves gastrointestinal disorder and counteracts gastroesophageal reflux.
Mucoadhesive properties has been evaluated by a new in vitro model (mucous membrane cell lines), predicting in vivo conditions. In these studies, MUCOSAVE™FG has shown a strong mucoadhesive activity (up to 60% of cell surface), higher than other mucoadhesive polymers such as hyaluronic acid and alginate (30% and 5% respectively).
The activity of MUCOSAVE™FG has been evaluated in a randomized, double-blind, placebo- controlled clinical trial carried out:
• on 100 volunteers with gastrointestinal discomfort
• treated with 400 mg/day of MUCOSAVE™FG
• for 8 weeks
• Assessment by valid and reliable questionnaires: Gastrointestinal Quality of Life index (GIQLI)
and GERD Symptom Assessment Scale (GSAS)
MUCOSAVE™FG supplementation showed a significant improvement of symptoms related to gastrointestinal discomfort after only 4 weeks.
SIGNIFICANT IMPROVEMENT OF GASTROINTESTINAL QUALITY OF LIFE INDEX (GIQLI) THANKS TO THE REDUCTION OF GASTROINTESTINAL SYMPTOMS
70% OF REDUCTION OF SYMPTOMS RELATED TO GASTROINTESTINAL DISCOMFORT